Idex (IEX) came out with quarterly earnings of $1.90 per share, beating the Zacks Consensus Estimate of $1.89 per share. This compares to earnings of $2.12 per share a year ago.
Weakness in the HST and FMT segments and escalating operating expenses are likely to hurt IEX's third-quarter results.
IEX is set to penetrate and diversify its offerings in key markets, such as semiconductor fabrication, medical technologies and water purification, with the acquisition of Mott.
I reiterate a 'Buy' rating for IDEX, with a fair price target of $220 per share, despite near-term headwinds in organic revenue and market softness. IDEX's acquisition of Mott Corporation for $1 billion is strategically favorable, enhancing their applied material science technology and potentially improving overall margins. Project delays and market weakness, particularly in the life science sector, have led to a 4% organic revenue decline and lowered full-year growth guidance.
Idex (IEX) reported earnings 30 days ago. What's next for the stock?
Softness in the analytical instrumentation, life sciences and semiconductor markets and increasing operating expenses weigh on IDEX (IEX). Unfavorable foreign currency movement is an added concern.
Although the revenue and EPS for Idex (IEX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
IDEX Corporation (NYSE:IEX ) Q2 2024 Earnings Conference Call August 1, 2024 10:30 AM ET Company Participants Wendy Palacios - Vice President, Investor Relations, FP&A Eric Ashleman - Chief Executive Officer & President Abhi Khandelwal - Senior Vice President & Chief Financial Officer Conference Call Participants Mike Halloran - Baird Vlad Bystricky - Citigroup Nathan Jones - Stifel Deane Dray - RBC Capital Markets Matt Summerville - D.A. Davidson Joe Giordano - Cowen Andrew Buscaglia - BNP Paribas Rob Wertheimer - Melius Research Operator Hello, and welcome to the IDEX Corporation Q2 2024 Earnings Conference Call and Webcast.
IDEX's (IEX) second-quarter 2024 net sales decrease 5% due to lower sales in the Fluid & Metering Technologies and Health & Science Technologies segments.
Idex (IEX) came out with quarterly earnings of $2.06 per share, beating the Zacks Consensus Estimate of $2.04 per share. This compares to earnings of $2.18 per share a year ago.
Weakness in the HST and FMT segments and escalating operating expenses are likely to hurt IDEX's (IEX) second-quarter results.
Idex (IEX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.